Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
ENTECAVIR 1-WATER 1,06 mg/stuk SAMENSTELLING overeenkomend met ; ENTECAVIR 1 mg/stuk
Alvogen Malta Operations (ROW) Ltd. Malta Life Sciences Park, Building 1, Level 4, Sir Temi Zammit Buildings SGN 3000 SAN GW
J05AF10
ENTECAVIR 1-WATER 1,06 mg/stuk SAMENSTELLING overeenkomend met ; ENTECAVIR 1 mg/stuk
Filmomhulde tablet
CELLULOSE, MICROKRISTALLIJN (E 460) ; CROSPOVIDON (E 1202) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; IJZEROXIDE ROOD (E 172) ; LACTOSE 1-WATER ; MACROGOL 400 ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; POLYSORBAAT 80 (E 433) ; TITAANDIOXIDE (E 171),
Oraal gebruik
Entecavir
Hulpstoffen: CELLULOSE, MICROKRISTALLIJN (E 460); CROSPOVIDON (E 1202); HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464); IJZEROXIDE ROOD (E 172); LACTOSE 1-WATER; MACROGOL 400; MAGNESIUMSTEARAAT (E 470b); MAÏSZETMEEL, GEPREGELATINEERD; POLYSORBAAT 80 (E 433); TITAANDIOXIDE (E 171);
2017-06-12
ENTECAVIR MONOHYDRATE_film-coated tablet_NL_en_NL-H-3828-001-002_name change_2021_09 PACKAGE LEAFLET: INFORMATION FOR THE USER ENTECAVIR ZENTIVA 0.5 MG FILMOMHULDE TABLETTEN ENTECAVIR ZENTIVA 1 MG FILMOMHULDE TABLETTEN Entecavir READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. Whatis and what it is used for 2. What you need to know before you take Lees het volledige document3. How to take 4. Possible side effects 5. How to store 6. Contents of the pack and other information 1. WHAT IS AND WHAT IT IS USED FOR TABLETS ARE ANTI-VIRAL MEDICINES, USED TO TREAT CHRONIC (LONG TERM) HEPATITIS B VIRUS (HBV) INFECTION IN ADULTS. can be used in people whose liver is damaged but still functions properly (compensated liver disease) and in people whose liver is damaged and does not function properly (decompensated liver disease). TABLETS ARE ALSO USED TO TREAT CHRONIC (LONG TERM) HBV INFECTION IN CHILDREN AND ADOLESCENTS AGED 2 YEARS TO LESS THAN 18 YEARS. can be used in children whose liver is damaged but still functions properly (compensated liver disease). Infection by the hepatitis B virus can lead to damage to the liver. reduces the amount of virus in your body, and improves the condition of the liver. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE DO NOT TAKE - if you are allergic to entecavir or any of the other ingredients of this medicine (listed in section 6).
ENTECAVIR MONOHYDRATE_film-coated tablet_NL_en_NL-H-3828-001-002_name change_2021_09 SUMMARY OF PRODUCT CHARACTERISTICS ENTECAVIR MONOHYDRATE_film-coated tablet_NL_en_NL-H-3828-001-002_name change_2021_09 1. NAME OF THE MEDICINAL PRODUCT Entecavir Zentiva 0.5 mg filmomhulde tabletten Entecavir Zentiva 1 mg filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Entecavir Zentiva 0.5 mg film-coated tablets Each tablet contains entecavir monohydrate corresponding to 0.5 mg entecavir. Entecavir Zentiva 1 mg film-coated tablets Each tablet contains entecavir monohydrate corresponding to 1 mg entecavir. Excipients with known effect: Each 0.5 mg film-coated tablet contains 121 mg lactose monohydrate. Each 1 mg film-coated tablet contains 242 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Entecavir Zentiva 0.5 mg film-coated tablets White oval shaped tablet with a size of about 10.1 mm x 3.7 mm with break line on both sides. The tablet can be divided into equal halves. Entecavir Zentiva 1 mg film-coated tablets Pink oval shaped tablet with a size of about 12.8 mm x 4.8 mm with break line on both sides. The tablet can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS ADULT INDICATION Treatment of chronic hepatitis B virus (HBV) infection (see section 5.1) in adults with: − compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. − decompensated liver disease (see section 4.4) For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B, see sections 4.2, 4.4 and 5.1. PAEDIATRIC POPULATION Treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to Lees het volledige document